Evidence map›Paper›PMID 41594119›Full record

ReviewAntibiotics (Basel, Switzerland)2026

Antimicrobial Resistance: How Can We Overcome the Problem?

Valerio Massimo Sora, Clementine Wallet, Gabriele Meroni, Thomas Loustau, Olivier Rohr, Alfonso Zecconi, Christian Schwartz

Abstract readReview
In one paragraph

Review in Antibiotics (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Some Newer Antibiotics Active AgainstAntibiotics (Basel, Switzerland) · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Valerio Massimo SoraSurgical and Dental Sciences-One Health Unit, Department of Biomedical, School of Medicine, University of Milan, Via Pascal 36, 20133 Milan, Italy.ORCID 0000-0003-1838-4885
Clementine WalletUPR CNRS 9002 ARN, IBMC, IUT Louis Pasteur, University of Strasbourg, 67300 Schiltigheim, France.ORCID 0000-0002-2388-4510
Gabriele MeroniSurgical and Dental Sciences-One Health Unit, Department of Biomedical, School of Medicine, University of Milan, Via Pascal 36, 20133 Milan, Italy.ORCID 0000-0003-2772-6410
Thomas LoustauUPR CNRS 9002 ARN, IBMC, IUT Louis Pasteur, University of Strasbourg, 67300 Schiltigheim, France.ORCID 0000-0003-4662-5228
Olivier RohrUPR CNRS 9002 ARN, IBMC, IUT Louis Pasteur, University of Strasbourg, 67300 Schiltigheim, France.ORCID 0000-0001-8992-2025
Alfonso ZecconiSurgical and Dental Sciences-One Health Unit, Department of Biomedical, School of Medicine, University of Milan, Via Pascal 36, 20133 Milan, Italy.ORCID 0000-0002-3127-8385
Christian SchwartzUPR CNRS 9002 ARN, IBMC, IUT Louis Pasteur, University of Strasbourg, 67300 Schiltigheim, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Antimicrobials are common drugs used to treat and prevent infectious diseases in plants, animals, and humans. Since their discovery in the mid-20th century, their use has dramatically increased for the benefit of humanity, and also for animal care. However, antimicrobial resistance soon appeared, which, according to the WHO, will limit or impede their use at the horizon of 2050. Indeed, antimicrobial resistance (AMR), which is a natural phenomenon in bacteria increased dramatically over the last 3 decades mainly due to the overuse and misuse of antibiotics in humans, animals, and plants. Apart from affecting human health, drug-resistant diseases also adversely affect plant and animal health, reduce agricultural productivity, and threaten food security. AMR affects all countries, regardless of economic status, and imposes high costs on health systems and national economies. Therefore, antimicrobial resistance should be studied and analyzed under the One Health paradigm. In mind of the One Health paradigm, to reduce and overcome AMR, we must take at least 3 complementary and integrated actions: (i) monitoring the resistome; (ii) developing protective strategies against antibiotic resistance; (iii) taking curative actions by designing new and original treatments. Moreover, the three actions must be conducted simultaneously due to the continuous adaptation of bacteria.

Indexed as

alternatives to antibioticsantimicrobial resistanceprotection strategiesresistome monitoring

Identifiers

PMID41594119
PMCPMC12837372

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.